• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

癌症发病机制中的免疫系统：潜在的治疗方法。

The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches.

机构信息

Indiana University School of Medicine, Riley CCRC 2641, 705 Riley Hospital Drive, Indianapolis, IN 46202, USA.

Indiana University School of Medicine, Riley CCRC 2623, 705 Riley Hospital Drive, Indianapolis, IN 46202, USA.

出版信息

J Immunol Res. 2016;2016:4273943. doi: 10.1155/2016/4273943. Epub 2016 Dec 26.

DOI:10.1155/2016/4273943
PMID:28116316
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5220497/
Abstract

Interplay among immune activation and cancer pathogenesis provides the framework for a novel subspecialty known as immunooncology. In the rapidly evolving field of immunooncology, understanding the tumor-specific immune response enhances understanding of cancer resistance. This review highlights the fundamentals of incorporating precision medicine to discover new immune biomarkers and predictive signatures. Using a personalized approach may have a significant, positive impact on the use of oncolytics to better guide safer and more effective therapies.

摘要

免疫激活与癌症发病机制的相互作用为一个新兴的亚专科提供了框架，这个亚专科被称为免疫肿瘤学。在免疫肿瘤学这个快速发展的领域中，对肿瘤特异性免疫反应的理解增强了对癌症耐药性的认识。本文重点介绍了将精准医学纳入发现新的免疫生物标志物和预测性特征的基本原理。采用个性化方法可能会对使用肿瘤溶瘤剂产生重大的积极影响，从而更好地指导更安全、更有效的治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7af3/5220497/ed10886b1be5/JIR2016-4273943.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7af3/5220497/c5c17c6f11b3/JIR2016-4273943.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7af3/5220497/2014ffc555f8/JIR2016-4273943.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7af3/5220497/ed10886b1be5/JIR2016-4273943.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7af3/5220497/c5c17c6f11b3/JIR2016-4273943.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7af3/5220497/2014ffc555f8/JIR2016-4273943.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7af3/5220497/ed10886b1be5/JIR2016-4273943.003.jpg

相似文献

1
The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches.癌症发病机制中的免疫系统：潜在的治疗方法。
J Immunol Res. 2016;2016:4273943. doi: 10.1155/2016/4273943. Epub 2016 Dec 26.
2
Towards In Silico Prediction of the Immune-Checkpoint Blockade Response.迈向免疫检查点阻断反应的计算预测。
Trends Pharmacol Sci. 2017 Dec;38(12):1041-1051. doi: 10.1016/j.tips.2017.10.002. Epub 2017 Oct 28.
3
Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.个性化肿瘤学与免疫学相遇：精准免疫治疗之路。
Cancer Discov. 2016 Jul;6(7):703-13. doi: 10.1158/2159-8290.CD-16-0146. Epub 2016 Apr 22.
4
Recent progress in therapeutic antibodies for cancer immunotherapy.癌症免疫治疗中治疗性抗体的最新进展。
Curr Opin Chem Biol. 2018 Jun;44:56-65. doi: 10.1016/j.cbpa.2018.05.006. Epub 2018 Jun 7.
5
Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?优化癌症免疫疗法：是否到了采用个体化预测性生物标志物的时候？
Crit Rev Clin Lab Sci. 2018 Nov;55(7):466-479. doi: 10.1080/10408363.2018.1499706. Epub 2018 Oct 2.
6
CANCER IMMUNOLOGY. The "cancer immunogram".癌症免疫学。“癌症免疫图谱”。
Science. 2016 May 6;352(6286):658-60. doi: 10.1126/science.aaf2834.
7
Cancer Immunotherapy and Identification of Prognostic and Predictive Biomarkers.癌症免疫疗法以及预后和预测生物标志物的鉴定
Biomed Res Int. 2018 Mar 20;2018:5184075. doi: 10.1155/2018/5184075. eCollection 2018.
8
(R)Evolutionary therapy: the potential of immunotherapy to fulfill the promise of personalized cancer treatment.（R）进化疗法：免疫疗法实现个性化癌症治疗前景的潜力。
J Natl Cancer Inst. 2014 Nov 27;107(1):347. doi: 10.1093/jnci/dju347. Print 2015 Jan.
9
Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.免疫治疗时代的高突变肿瘤：个性化医疗范式
Eur J Cancer. 2017 Oct;84:290-303. doi: 10.1016/j.ejca.2017.07.026. Epub 2017 Aug 29.
10
Personalized medicine in oncology: the future is now.肿瘤个性化医学：未来已来。
Nat Rev Drug Discov. 2010 May;9(5):363-6. doi: 10.1038/nrd3181.

引用本文的文献

1
Effects of anlotinib combined with camrelizumab and chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma on tumor immune microenvironment.安罗替尼联合卡瑞利珠单抗及化疗作为晚期食管鳞状细胞癌一线治疗对肿瘤免疫微环境的影响
J Gastrointest Oncol. 2025 Aug 30;16(4):1366-1379. doi: 10.21037/jgo-2025-30. Epub 2025 Aug 16.
2
Diagnosis of cancer, autoimmune and infectious diseases and prediction of the therapy effectiveness based on the individual's immunotype.基于个体免疫类型对癌症、自身免疫性疾病和传染病进行诊断，并预测治疗效果。
Front Immunol. 2025 Aug 29;16:1658970. doi: 10.3389/fimmu.2025.1658970. eCollection 2025.
3

本文引用的文献

1
Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.个性化肿瘤学与免疫学相遇：精准免疫治疗之路。
Cancer Discov. 2016 Jul;6(7):703-13. doi: 10.1158/2159-8290.CD-16-0146. Epub 2016 Apr 22.
2
FDA Approval: Blinatumomab.FDA 批准：blinatumomab。
Clin Cancer Res. 2015 Sep 15;21(18):4035-9. doi: 10.1158/1078-0432.CCR-15-0612.
3
Glycosylation in cancer: mechanisms and clinical implications.癌症中的糖基化：机制与临床意义。
Investigating the effects of pcDNA3 polybia-MP1 on the apoptosis induction in lung cancer cell line.
研究pcDNA3多比亚-MP1对肺癌细胞系凋亡诱导的影响。
Sci Rep. 2025 Aug 2;15(1):28226. doi: 10.1038/s41598-025-13439-9.
4
InGeTox: a human-based in vitro platform to evaluate lentivirus/host interactions that contribute to genotoxicity.InGeTox：一个基于人体的体外平台，用于评估导致基因毒性的慢病毒/宿主相互作用。
Gene Ther. 2025 Jul 15. doi: 10.1038/s41434-025-00550-9.
5
From seabed to sickbed: lessons gained from allorecognition in marine invertebrates.从海底到病床：从海洋无脊椎动物的同种异体识别中获得的经验教训。
Front Immunol. 2025 Apr 10;16:1563685. doi: 10.3389/fimmu.2025.1563685. eCollection 2025.
6
Clinical Significance of Blood Cell-Derived Inflammation Markers in Assessing Potential Early and Late Postoperative Complications in Patients with Colorectal Cancer: A Systematic Review.血细胞源性炎症标志物在评估结直肠癌患者术后早期和晚期潜在并发症中的临床意义：一项系统综述
J Clin Med. 2025 Apr 7;14(7):2529. doi: 10.3390/jcm14072529.
7
The Prognostic Value and Immunomodulatory Role of Spsb2, a Novel Immune Checkpoint Molecule, in Hepatocellular Carcinoma.新型免疫检查点分子Spsb2在肝细胞癌中的预后价值及免疫调节作用
Genes (Basel). 2025 Mar 17;16(3):346. doi: 10.3390/genes16030346.
8
Analysis of Body Composition and Levels of Antimicrobial Peptides in Patients with Basal Cell Carcinoma: A Preliminary Study.基底细胞癌患者身体成分与抗菌肽水平分析：一项初步研究
J Clin Med. 2025 Jan 10;14(2):419. doi: 10.3390/jcm14020419.
9
The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives.癌症免疫疗法的演变：对其历史和当前观点的全面综述。
Korean J Clin Oncol. 2024 Dec;20(2):51-73. doi: 10.14216/kjco.24009. Epub 2024 Dec 31.
10
Imaging of tumor-associated macrophage dynamics during immunotherapy using a CD163-specific nanobody-based immunotracer.使用基于CD163特异性纳米抗体的免疫示踪剂对免疫治疗期间肿瘤相关巨噬细胞动力学进行成像。
Proc Natl Acad Sci U S A. 2024 Dec 24;121(52):e2409668121. doi: 10.1073/pnas.2409668121. Epub 2024 Dec 18.
Nat Rev Cancer. 2015 Sep;15(9):540-55. doi: 10.1038/nrc3982. Epub 2015 Aug 20.
4
Big opportunities for small molecules in immuno-oncology.小分子在肿瘤免疫治疗中的巨大机遇。
Nat Rev Drug Discov. 2015 Sep;14(9):603-22. doi: 10.1038/nrd4596. Epub 2015 Jul 31.
5
Immunotherapy: making the case for precision medicine.免疫疗法：精准医学的实例论证
Sci Transl Med. 2015 Mar 25;7(280):280ed3. doi: 10.1126/scitranslmed.aaa9846.
6
Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.免疫疗法与癌基因靶向疗法相结合：黑色素瘤治疗的新途径。
Front Immunol. 2015 Feb 9;6:46. doi: 10.3389/fimmu.2015.00046. eCollection 2015.
7
Cancer statistics, 2015.癌症统计数据，2015 年。
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.
8
Introduction to a clinical review series on aggressive B-cell lymphoma.侵袭性B细胞淋巴瘤临床综述系列介绍。
Blood. 2015 Jan 1;125(1):1-2. doi: 10.1182/blood-2014-09-594580. Epub 2014 Dec 11.
9
Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer.嵌合抗原受体（CAR）-T细胞疗法治疗癌症面临的挑战。
Discov Med. 2014 Nov;18(100):265-71.
10
TLR7 induces anergy in human CD4(+) T cells.Toll样受体7（TLR7）可诱导人CD4(+) T细胞无反应性。
Nat Immunol. 2015 Jan;16(1):118-28. doi: 10.1038/ni.3036. Epub 2014 Nov 17.